129 related articles for article (PubMed ID: 29212486)
21. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
22. Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guérin instillations for superficial bladder cancer.
Kaneko T; Fujita K; Homma Y
Int J Urol; 2006 Mar; 13(3):294-5. PubMed ID: 16643629
[TBL] [Abstract][Full Text] [Related]
23. Is the role of intravesical bacillus Calmette-Guérin in non-muscle-invasive bladder cancer changing?
Ayres BE; Griffiths TR; Persad RA
BJU Int; 2010 Feb; 105 Suppl 2():8-13. PubMed ID: 20089092
[No Abstract] [Full Text] [Related]
24. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
[TBL] [Abstract][Full Text] [Related]
25. Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin.
Packiam VT; Johnson SC; Steinberg GD
Cancer; 2017 Feb; 123(3):390-400. PubMed ID: 28112819
[TBL] [Abstract][Full Text] [Related]
26. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
Nielsen ME; Smith AB; Pruthi RS; Guzzo TJ; Amiel G; Shore N; Lotan Y
BJU Int; 2012 Oct; 110(7):967-72. PubMed ID: 22487336
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.
Savic S; Zlobec I; Thalmann GN; Engeler D; Schmauss M; Lehmann K; Mattarelli G; Eichenberger T; Dalquen P; Spieler P; Schoenegg R; Gasser TC; Sulser T; Forster T; Zellweger T; Casella R; Bubendorf L
Int J Cancer; 2009 Jun; 124(12):2899-904. PubMed ID: 19230026
[TBL] [Abstract][Full Text] [Related]
28. [Granulomatous hepatitis revealing a Mycobacterium bovis widespread infection following intravesical BCG therapy].
Raffray L; Rivière P; Bonnet H; Duffau P; Longy-Boursier M
Rev Med Interne; 2015 Sep; 36(9):626-30. PubMed ID: 25467298
[TBL] [Abstract][Full Text] [Related]
29. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
30. Isolated renal tuberculosis following intravesical Bacillus Calmette-Guérin therapy for bladder cancer.
Wada Y; Sugiyama Y; Kikukawa H; Kuwahara T; Takahashi W; Takamiya T; Ueda S
Urol Int; 2004; 72(3):257-60. PubMed ID: 15084773
[TBL] [Abstract][Full Text] [Related]
31. The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?
Hofbauer SL; Shariat SF; Chade DC; Sarkis AS; Ribeiro-Filho LA; Nahas WC; Klatte T
Urol Int; 2016; 96(1):46-50. PubMed ID: 26555711
[TBL] [Abstract][Full Text] [Related]
32. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
[TBL] [Abstract][Full Text] [Related]
33. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
Herr HW; Dalbagni G
BJU Int; 2013 May; 111(6):984-7. PubMed ID: 23351086
[TBL] [Abstract][Full Text] [Related]
34. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
35. Intravesical bacille Calmette-Guérin eradicates bacteriuria in antibiotic-naïve bladder cancer patients.
Herr HW
Eur Urol; 2013 May; 63(5):832-5. PubMed ID: 22921719
[TBL] [Abstract][Full Text] [Related]
36. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
37. Bladder and penile lesions with inguinal adenopathy after intravesical Bacillus Calmette-Guerin (BCG) treatment.
Yates J; Stein B
Urology; 2007 Dec; 70(6):1223.e15-7. PubMed ID: 18158061
[TBL] [Abstract][Full Text] [Related]
38. External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin.
Kohjimoto Y; Kusumoto H; Nishizawa S; Kikkawa K; Kodama Y; Ko M; Matsumura N; Hara I
Int J Urol; 2014 Dec; 21(12):1201-7. PubMed ID: 25074295
[TBL] [Abstract][Full Text] [Related]
39. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
[TBL] [Abstract][Full Text] [Related]
40. Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature.
Bernini L; Manzini CU; Giuggioli D; Sebastiani M; Ferri C
Autoimmun Rev; 2013 Oct; 12(12):1150-9. PubMed ID: 23816569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
